Abbott Laboratories (ABT) Stock Price, News & Analysis

Company Overview

Abbott Laboratories (NYSE: ABT), founded in 1888 by Wallace C. Abbott, is a global healthcare company committed to discovering, developing and manufacturing a wide array of therapeutic and diagnostic products. Headquartered in Abbott Park, Illinois, the company has evolved from its pharmaceutical origins into a diversified provider of medical devices, diagnostics, nutrition and branded generic pharmaceuticals, serving patients and healthcare professionals in more than 160 countries.

The company’s medical devices division offers products designed to improve outcomes in cardiovascular care, neuromodulation and structural heart interventions. Its portfolio includes interventional cardiology tools, implantable cardiac rhythm management systems and neuromodulation therapies. In diagnostics, Abbott provides immunoassay and clinical chemistry platforms, point-of-care instruments, molecular diagnostics and rapid tests that enable accurate and timely clinical decisions across hospital laboratories, physician offices and remote settings.

In the nutrition segment, Abbott delivers science-based infant formulas, pediatric and adult nutritional products that support life-stage health and wellness. These offerings draw on the company’s expertise in vitamins, minerals and specialty nutrients to address global dietary needs. Abbott’s branded generics unit focuses on high-quality, cost-effective therapies in therapeutic areas such as women’s health, cardiovascular disease and metabolic disorders, with an emphasis on expanding access to medicines in emerging markets.

With a strong commitment to research and development, Abbott collaborates with academic institutions, healthcare providers and nonprofit organizations to drive medical innovation and improve patient care. Under the leadership of President and Chief Executive Officer Robert B. Ford, the company continues to uphold rigorous quality and regulatory standards while advancing its mission to enhance lives through pioneering healthcare solutions.

Key Stats

• Today's Range: $133.20 to $135.24
• 50-Day Range: $128.45 to $138.13
• 52-Week Range: $99.71 to $141.23
• Volume: 3.11 million shs
• Average Volume: 6.16 million shs
• Market Capitalization: $232.61 billion
• P/E Ratio: 17.34
• Dividend Yield: 1.77%
• Price Target: $142.61
• Consensus Rating: Moderate Buy

Abbott Laboratories Stock Analysis - MarketRank™

Abbott Laboratories scored higher than 98% of companies evaluated by MarketBeat, and ranked 35th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Abbott Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 14 buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Abbott Laboratories has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 11.48%

Earnings Growth

Earnings for Abbott Laboratories are expected to grow by 11.48% in the coming year, from $5.14 to $5.73 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Abbott Laboratories is 17.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Abbott Laboratories is 17.34, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.64.

Price to Earnings Growth Ratio

Abbott Laboratories has a PEG Ratio of 2.55. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Abbott Laboratories has a P/B Ratio of 4.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.20% of the float of Abbott Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Abbott Laboratories has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Abbott Laboratories has recently increased by 3.53%, indicating that investor sentiment is decreasing.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Abbott Laboratories pays a meaningful dividend of 1.76%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Abbott Laboratories has been increasing its dividend for 54 years.

Dividend Coverage

The dividend payout ratio of Abbott Laboratories is 30.61%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 41.19% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.10

Percentage of Shares Shorted

1.20% of the float of Abbott Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Abbott Laboratories has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Abbott Laboratories has recently increased by 3.53%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.24

News Sentiment

Abbott Laboratories has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 65 news articles for Abbott Laboratories this week, compared to 38 articles on an average week.

Search Interest

Only 45 people have searched for ABT on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.

MarketBeat Follows

Only 17 people have added Abbott Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Abbott Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $337,116.00 in company stock.

Percentage Held by Insiders

Only 0.46% of the stock of Abbott Laboratories is held by insiders.

Percentage Held by Institutions

75.18% of the stock of Abbott Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABT Stock Analysis - Frequently Asked Questions

How have ABT shares performed this year?

Abbott Laboratories' stock was trading at $113.11 at the beginning of 2025. Since then, ABT shares have increased by 18.2% and is now trading at $133.6950.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) released its quarterly earnings data on Wednesday, April, 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.07 by $0.02. The healthcare product maker had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.38 billion. Abbott Laboratories had a net margin of 31.89% and a trailing twelve-month return on equity of 19.01%.
Read the conference call transcript.

Does Abbott Laboratories have any subsidiaries?

Abbott Laboratories subsidiaries include Cephea Valve Technologies, Alere, St. Jude Medical, Kalila Medical, Tendyne Holdings Inc., Veropharm, Topera Inc., and more.

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' top institutional investors include Park National Corp OH (0.01%), First Financial Bank Trust Division (0.01%), Jacobs & Co. CA and Neville Rodie & Shaw Inc.. Insiders that own company stock include Daniel J Starks, Robert B Ford, Jr Robert E Funck, Jr Robert E Funck, Daniel Gesua Sive Salvadori, John F Ginascol, Andrea F Wainer, Lisa D Earnhardt, Joseph J Manning, Randel William Woodgrift, Julie L Tyler, Eric Shroff, John A Jr Mccoy and Fernando Mateus.
View institutional ownership trends.

How do I buy shares of Abbott Laboratories?

Shares of ABT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Abbott Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Abbott Laboratories investors own include JPMorgan Chase & Co. (JPM), Chevron (CVX), NVIDIA (NVDA), Predictive Oncology (POAI), Bank of America (BAC), Meta Platforms (META) and AbbVie (ABBV).

Company Calendar

• Record date for 5/15 Dividend: 4/15/2025
• Ex-Dividend for 5/15 Dividend: 4/15/2025
• Last Earnings: 4/16/2025
• Dividend Payable: 5/15/2025
• Today: 7/05/2025
• Record date for 8/15 Dividend: 7/15/2025
• Ex-Dividend for 8/15 Dividend: 7/15/2025
• Next Earnings (Estimated): 7/17/2025
• Dividend Payable: 8/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:ABT
• CIK: 1800
• Web: www.abbott.com
• Phone: (224) 667-6100
• Fax: 847-937-1511
• Employees: 114,000
• Year Founded: 1888

Price Target and Rating

• Average Stock Price Target: $142.61
• High Stock Price Target: $160.00
• Low Stock Price Target: $127.00
• Potential Upside/Downside: +6.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.76
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): $7.71
• Trailing P/E Ratio: 17.34
• Forward P/E Ratio: 26.01
• P/E Growth: 2.55
• Net Income: $13.40 billion
• Net Margins: 31.89%
• Pretax Margin: 17.37%
• Return on Equity: 19.01%
• Return on Assets: 10.82%

Debt

• Debt-to-Equity Ratio: 0.26
• Current Ratio: 1.78
• Quick Ratio: 1.27

Sales & Book Value

• Annual Sales: $41.95 billion
• Price / Sales: 5.54
• Cash Flow: $6.55 per share
• Price / Cash Flow: 20.42
• Book Value: $27.62 per share
• Price / Book: 4.84

Miscellaneous

• Outstanding Shares: 1,739,840,000
• Free Float: 1,731,833,000
• Market Cap: $232.61 billion
• Optionable: Optionable
• Beta: 0.73